NRXP · NASDAQ

NRx Pharmaceuticals, Inc.

Q: How do I get NRXP news from the API?

Call GET /v1/news?tickers=NRXP. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

$2.15 -0.50 (-18.71%)

Company overview

NRX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19-related respiratory failure, as well as NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior or ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Market cap: $93.1M
Employees: 2
Headquarters: Wilmington, DE
Website: nrxpharma.com
CEO: Jonathan C. Javitt
Listed: December 4, 2017
P/E: -1.68
Dividend yield: 0.00%

Company financials

Revenue: $2.3M
Gross profit: $851,000
Operating income: -$17.2M
EBITDA: -$30.7M
Net income: -$24.5M
EPS: -$1.28
Total assets: $11.9M
Total debt: $934,000
Gross margin: 37.11%
Net margin: -1,070.26%
Earnings yield: -59.39%

Revenue segmentation

By product (FY 2025)

By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

NRXP 1D NASDAQ O2.73H2.77L2.64C2.65-0.04 (-1.67%)Vol176.12K

News

Ticker	Type	Headline	Source	Published
NRXPNRx Pharmaceuticals, Inc.	Stock news	NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript	Seeking Alpha	Oct 30, 11:18:27 AM ET
NRXPNRx Pharmaceuticals, Inc.	Stock news	NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection	MarketBeat	Oct 30, 10:17:12 AM ET
NRXPNRx Pharmaceuticals, Inc.	Press release	NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date	GlobeNewswire	Oct 30, 7:00:00 AM ET
NRXPNRx Pharmaceuticals, Inc.	Press release	NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine	GlobeNewswire	Oct 29, 4:00:42 PM ET
NRXPNRx Pharmaceuticals, Inc.	Press release	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine	GlobeNewswire	Oct 19, 8:30:00 AM ET
NRXPNRx Pharmaceuticals, Inc.	Press release	NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine	GlobeNewswire	Oct 15, 8:27:44 AM ET
NRXPNRx Pharmaceuticals, Inc.	Press release	NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression	GlobeNewsWire	Sep 30, 7:00:00 AM ET
NRXPNRx Pharmaceuticals, Inc.	Stock news	NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine	GlobeNewsWire	Sep 15, 3:11:00 PM ET
NRXPNRx Pharmaceuticals, Inc.	Stock news	NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry	Seeking Alpha	Sep 14, 10:26:27 AM ET
NRXPNRx Pharmaceuticals, Inc.	Press release	GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)	GlobeNewsWire	Sep 14, 7:00:00 AM ET
NRXPNRx Pharmaceuticals, Inc.	Press release	NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System	GlobeNewswire	Sep 11, 7:00:00 AM ET
NRXPNRx Pharmaceuticals, Inc.	Press release	NRx Pharmaceuticals to Participate in Upcoming Investor Conferences	GlobeNewswire	Sep 8, 7:00:00 AM ET
NRXPNRx Pharmaceuticals, Inc.	Stock news	NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript	Seeking Alpha	Aug 18, 11:02:00 AM ET
NRXPNRx Pharmaceuticals, Inc.	Press release	NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET	GlobeNewsWire	Aug 17, 7:00:00 AM ET
NRXPNRx Pharmaceuticals, Inc.	Stock news	NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates	Zacks Investment Research	Aug 14, 9:16:05 PM ET
NRXPNRx Pharmaceuticals, Inc.	Stock news	NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript	Seeking Alpha	Aug 10, 11:38:27 AM ET
NRXPNRx Pharmaceuticals, Inc.	Stock news	NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles	MarketBeat	Aug 10, 10:05:19 AM ET
NRXPNRx Pharmaceuticals, Inc.	Press release	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans	GlobeNewsWire	Aug 7, 4:01:00 PM ET
NRXPNRx Pharmaceuticals, Inc.	Press release	NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.	GlobeNewsWire	Jun 5, 8:50:00 AM ET
NRXPNRx Pharmaceuticals, Inc.	Press release	NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option	GlobeNewsWire	Jun 4, 5:12:00 PM ET

FAQ

Questions about NRx Pharmaceuticals, Inc.

What does NRx Pharmaceuticals, Inc. do?

What is NRXP's market cap?

NRx Pharmaceuticals, Inc. (NRXP) is a listed stock with a live quote. The latest market cap on this page is $93.1M.

Where is NRx Pharmaceuticals, Inc. headquartered?

NRx Pharmaceuticals, Inc. is headquartered in Wilmington, DE.

How do I get NRXP news from the API?

Call GET /v1/news?tickers=NRXP. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

How far back does NRXP news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for NRXP, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.

Is the NRXP price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs